Question · asked by 1 review

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo): Bleeding duration

Population
People with haemophilia (A or B) undergoing minor oral surgery or dental extractions
Intervention
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid)
Comparison
Placebo, no intervention or usual care (with or without placebo)
Outcome
Bleeding duration

The review found no eligible studies for this question.

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)
Bleeding duration · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions
The review found no eligible studies for this question.
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… (2019) · Cochrane All outcomes
This outcome was not reported in either of the trials.0 studiesNo studies found

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery…
2019 · Cochrane All outcomes
2019-03Not listedNot assessed
How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.